Medicine & Life Sciences
Busulfan
82%
Clinical Trials
63%
fludarabine
58%
Survival
58%
Acute Myeloid Leukemia
56%
Phase II Clinical Trials
54%
Stem Cell Transplantation
46%
Melphalan
41%
Therapeutics
41%
Sample Size
37%
Bayes Theorem
35%
Progression-Free Survival
34%
Allogeneic Cells
34%
Hematopoietic Stem Cell Transplantation
32%
Drug Therapy
32%
Clinical Trials, Phase I
31%
Random Allocation
29%
Neoplasms
28%
Prostatic Neoplasms
27%
Myelodysplastic Syndromes
27%
Transplants
24%
gemcitabine
22%
Safety
22%
Cytarabine
22%
Imatinib Mesylate
22%
Homologous Transplantation
22%
Appointments and Schedules
21%
Docetaxel
20%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
20%
Cyclophosphamide
19%
Leukemia
18%
Refractory Anemia with Excess of Blasts
18%
Tissue Donors
17%
Maximum Tolerated Dose
17%
Graft vs Host Disease
17%
Platelet-Derived Growth Factor Receptors
17%
Androgens
16%
Idarubicin
16%
Clofarabine
15%
Recurrence
15%
Renal Cell Carcinoma
15%
Sarcoma
14%
Bone Marrow Transplantation
14%
Behavior Therapy
14%
Multiple Myeloma
13%
Esophageal Neoplasms
13%
Granulocyte Colony-Stimulating Factor
12%
Cell Transplantation
12%
Myeloid Leukemia
12%
Vorinostat
12%
Mathematics
Clinical Trials
100%
Toxicity
94%
Dose
76%
Design
72%
Dose Finding
50%
Efficacy
45%
Cancer
38%
Covariates
26%
Monitoring
25%
Survival Time
23%
Therapy
22%
Phase I Trial
21%
Progression
20%
Group Sequential
19%
Oncology
19%
Chemotherapy
18%
Randomisation
18%
Subgroup
18%
Simulation Study
17%
Leukemia
17%
Bayesian Nonparametrics
16%
Sample Size
16%
Safety
16%
Optimise
15%
Acute
14%
Count
14%
Variable Selection
14%
Bayesian Design
14%
Strategy
14%
Effective Sample Size
13%
Treatment Effects
13%
Schedule
13%
Multiple Outcomes
12%
Bayesian Model
12%
Cell
12%
Bayesian Variable Selection
12%
Evaluation
11%
Two-stage Design
11%
Prostate Cancer
11%
Recurrent Events
11%
Regression Model
11%
Transplantation
11%
Trade-offs
11%
Evaluate
11%
Randomized Clinical Trial
11%
Count Data
11%
Biomarkers
10%
Screening
10%
Competing Risks
10%
Model
10%